US-based Ocata develops and commercializes regenerative ophthalmology therapeutics. The company’s principal R&D and commercial efforts relate to its Regenerative Ophthalmology programs and involve development of therapies to treat
Cotellic and Zelboraf are not used to treat melanoma with a normal BRAF gene. Cotellic is Genentech’s seventh new medicine approved by the FDA in the past five
As company spokesperson, Michael Thompson, noted, Nitrosolution first launched its original nitric oxide booster product Nitroxyl about 2 years ago. While Nitroxyl is designed for people over the
TaNeDS, which began in 2011 as part of Daiichi Sankyo’s open innovation program, selects researchers from universities and public research centers in Japan, and Daiichi Sankyo will soon
The facility has been approved by the Swiss Agency for Therapeutic Products ("Swissmedic"), the Swiss equivalent to the US FDA. Stemedica has fully executed the transfer of its
NGP 555 is a first in class small molecule for the treatment and prevention of Alzheimer’s disease. NGP 555 is an amyloid modulator showing good brain penetration in
Under the agreement, Morphotek provides to Blaze an exclusive, worldwide, royalty-bearing license to develop, license, and once approved, commercialize a potential tumor-targeting chlorotoxin derivative linked to a near-infrared
The collaboration will focus on promoting the development of biomedical innovations from companies located in the park that could help meet the growing demand to fill global pharmaceutical
Repatha is one of a new class of biotechnology medicines known as PCSK9 inhibitors. The drugs have demonstrated a promising new approach for treating elevated LDL cholesterol in
This study is a collaborative effort between MediciNova and Drs. Nazem Atassi and Haruhiko Banno, Principal Investigators at Massachusetts General Hospital’s (MGH) Neurological Clinical Research Institute (NCRI) and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.